BC
YMAB

Brookfield Corp’s Y-mAbs Therapeutics YMAB Stock Holding History

Brookfield Corp’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-179,236
Closed -$5.12M – 748
2021
Q3 		$5.12M Buy
179,236
+12,582
+8% +$397K 0.02% 219
2021
Q2 		$5.63M Buy
166,654
+58,954
+55% +$1.89M 0.03% 193
2021
Q1 		$3.26M Buy
107,700
+63,700
+145% +$2.61M 0.02% 222
2020
Q4 		$2.18M Buy
+44,000
New +$2.04M 0.01% 272

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Brookfield Corp's YMAB Position: Q4 2021 in Review

Brookfield Corp sold out of Y-mAbs Therapeutics (YMAB) in Q4 2021, closing a stake of 179,236 shares — an estimated $5.12M sold.

Brookfield Corp first reported a position in YMAB in Q4 2020 and held it in 4 quarters. The position peaked at $5.63M in Q2 2021. 97 funds tracked by Wall St. Rank hold YMAB as of Q4 2021.

  • Brookfield Corp reported no remaining Y-mAbs Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Brookfield Corp sold 179,236 Y-mAbs Therapeutics shares in Q4 2021, an estimated $5.12M.
  • Brookfield Corp first reported a position in Y-mAbs Therapeutics in Q4 2020 and held it in 4 quarters.
  • Brookfield Corp's Y-mAbs Therapeutics position peaked at $5.63M in Q2 2021.
  • 97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2021.

Based on Brookfield Corp's 13F filing for Q4 2021, filed 14 Feb 2022.